摘要
目的:检测多发性骨髓瘤(MM)患者脱嘌呤/脱嘧啶核酸内切酶(apurinic/apyrimidinicendonuclease,APEl)基因表达,探讨其与MM疗效的关系。方法:采用双标免疫荧光结合激光共聚焦显微镜、免疫细胞化学分析MM细胞系KM3、32例MM患者和10例正常自愿者骨髓标本中检测APE1蛋白表达及定位。结果:MM患者骨髓标本有Apel和CD38蛋白共表达;在作为阳性对照的MM细胞系KM3中胞核、胞核/胞浆、胞浆均有APEl表达,其中尤以胞核明显;APEl胞浆阳性分度在正常对照组、初治组、复发或难治组间依次增高(P<0.01或0.05)。结论:APEl蛋白表达强度与MM疗效有关,APEl基因表达增强可能是MM患者预后不良的指标之一。
Objective:To detect expression of the apurinic/apyrimidinic endonuclease(APEl) protein in multiple myeloma (MM) and evaluate its clinical significance. Metheds: Expression and location of APEl protein was detected in MM cell line KM3,bone marrow specimens of 32 MM patients and 10 normal volunteers using immunofluorescence double staining method and laser cofocal scanning microscopy and immunocytochemical staining. Results: Apel and CD38co - expressed in bone marrow specimen of MM. Nuclear, nucleus/cytoplasmic and cytoplasmic types of Apel positive staining could be noticed in MM. Expression of APEl gene in nucleus were significantly elevated compared to those in nucleus/cytoplasm and cytoplasm. In normal control group, untreated patients group, relapse or refractory group, the positive degree of cytoplasmic staining were increased significantly in turn ( p 〈 0.01 or 0.05 ). Conclusion: Expression degree of APEl protcin was asseeiated with MM treatment purpose. High expression of APEl protein may predict poor prognosis.
出处
《激光杂志》
CAS
CSCD
北大核心
2005年第4期89-90,共2页
Laser Journal